Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 11/20 | 0.39 |
| ▸ | EEF2K | O00418 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | WNT1 | P04628 | 4/20 | 0.32 |
| ▸ | GSK3B | P49841 | 4/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136527 | 0.88 | CD38 (0.39) | CD38EEF2KMYCADORA3ADORA2A | |
| SCHEMBL25136381 | 0.84 | CD38 (0.45) | CD38 | |
| SCHEMBL29182166 | 0.79 | CD38 (0.50) | CD38 | |
| SCHEMBL25136368 | 0.77 | CD38 (0.49) | CD38 | |
| SCHEMBL29182163 | 0.77 | CD38 (0.38) | CD38EEF2KADORA3ADORA2AADORA2B | |
| SCHEMBL30363838 | 0.77 | CD38 (0.52) | CD38 | |
| SCHEMBL30182551 | 0.77 | CD38 (0.59) | CD38 | |
| SCHEMBL25136183 | 0.77 | CD38 (0.52) | CD38 | |
| SCHEMBL25136131 | 0.77 | CD38 (0.59) | CD38 | |
| SCHEMBL29182222 | 0.77 | CD38 (0.59) | CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117813296-A | CD38 modulators and methods of use thereof | 赛特凯恩蒂克公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | CD38 1/4885EEF2K 4768/4885MYC 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.